Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer
A phase 3 trial of Palifermin in Head and neck squamous cell carcinoma, run by Swedish Orphan Biovitrum, completed.
Overview
Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer is a phase 3 interventional study registered as NCT00101582 by Swedish Orphan Biovitrum, with 188 participants recorded, started 2005-08 and reaching its primary completion in 2007-09. Interventions recorded: Placebo, palifermin, cisplatin chemotherapy, Radiotherapy. Conditions recorded: Mucositis, Solid Tumors, Stomatitis, Head and Neck Cancer, Squamous Cell Carcinoma.
Linked to the drug Palifermin because the registry names it among its interventions and Head and neck squamous cell carcinoma among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialA Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Multiple Myeloma
Shares Palifermin, Sobi (Swedish Orphan Biovitrum) and the tag pipeline.
- TrialPalifermin for the Reduction of Oral Mucositis in Single-dose Evaluation (PROMISE)
Shares Palifermin, Sobi (Swedish Orphan Biovitrum) and the tag pipeline.
- TrialPacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia
Shares Sobi (Swedish Orphan Biovitrum) and the tag pipeline.
- TrialMIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients
Shares Head and neck squamous cell carcinoma and the tag pipeline.
- TrialA Study of DM005 in Patients With Advanced Solid Tumors
Shares Head and neck squamous cell carcinoma and the tag pipeline.
- TrialA Phase I/IIa Clinical Trial to Investigate BVAC-E6E7 in Subjects With HPV Positive HNSCC.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
- TrialIntratumoral N17350 in Advanced Solid Tumors
Shares Head and neck squamous cell carcinoma and the tag pipeline.
- TrialResponse Adaptive Radiotherapy Following Immunotherapy-based Induction for Non-HPV Related HNSCC
Shares Head and neck squamous cell carcinoma and the tag pipeline.